ClinicalTrials.gg
RecruitingNCT03910465Updated Nov 9, 2026

Children and Adults With Chordoma

An observational study in Chordoma, sponsored by National Cancer Institute (NCI). Recruiting at 1 site in United States. Open to participants aged 2 Years and older. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by National Cancer Institute (NCI) · Observational

How we know

From the registry’s dates

  • Started Apr 2019; still recruiting 7 years 7 months later.
Updated Oct 1, 2026Eligibility revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
300
Ages
2 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 44 studies in Chordoma with a site in United States — 6 open to participants now, 16 under way, none of them phase 3. Chordoma · United States.

Planned enrollment
3rd of 11
300 · median 150
Started
2019
with 3 others
Observational
11 of 44
4 open now
Primary completion
2029-12
later than 11 of 14 live
Registered
28th of 44
by date
Lead sponsor
7 of 44
National Cancer Institute (NCI)

Among the 44 studies in Chordoma with a site in United States, this one is the 3rd largest by planned enrollment of the 11 observational ones that give a count, is one of 4 that started in 2019, is one of 11 observational ones, reaches primary completion later than 11 of the 14 other live ones, and was the 28th registered.

Chordoma

68 studies on the registry are indexed under Chordoma; 15 are open to participants now.

Browse Chordoma studies →

Open to participants now

6 of the 44 studies in Chordoma with a site in United States are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 12 Chordoma studies recruiting now, 9 (75%) set no upper age limit and 1 (8%) stops at 75 or younger; 3 take children under 18; 1 takes healthy volunteers.

This study: 2 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies in Chordoma with a site in United States, or all of them as a file.
02

Study summary

Background:

Chordoma is a rare type of bone cancer. It occurs in the skull base or spine. Researchers want to study people with chordoma in different ways. They hope this will help them design better future treatments and supportive care studies for this disease.

Objective:

To learn more about chordoma by looking at its clinical course, how it appears on imagine scans, and how it responds to therapies and treatments.

Eligibility:

People ages 2 and older with chordoma who are enrolled in NCI protocol 19-C-0016

Design:

Participants will be screened with their medical history.

Participants will have a visit to examine their disease. This will include:

  • Physical exam
  • Neurologic exam
  • CT scan and MRI: Participants will lie on a table. The table will slide into a machine. The machine will take pictures of the body.

Participants will have other tests every 6-12 months:

  • Smell test
  • Surveys to assess their emotional, physical, and behavioral well-being and needs
  • Cognitive function tests

Participants or their home doctors will be contacted every 6 12 months. They will be asked to provide information about their disease. This could include test results and imaging evaluations.

Some participants may be asked to come to the clinic for more visits.

Read the detailed description

Background:

  • Chordomas are a rare tumor with an incidence of 325 new cases per year in the United States. Pediatric chordomas are very rare and comprise only 5% of all chordoma cases.
  • The standard therapy for localized primary or recurrent chordomas is surgical resection. However, complete surgical resection is often not possible due to the location of the chordoma.
  • For chordomas that cannot be surgically resected, treatment options are limited. Currently, no standard therapy approach exists for recurrent chordomas. In addition, there are no FDA approved medical therapies for chordoma.
  • The natural history of pediatric and adult chordoma is incompletely understood. Patients with chordoma seek expert advice in the management of their care.
  • The NCI has basic and clinical expertise and research interest in chordoma. The planned natural history study as part of the NCI POB Rare Tumor Patient Engagement Network (RTPEN) will allow for comprehensive evaluation and recommendations to these patients while longitudinally collecting clinical, epidemiologic and biological data.

Objective:

-To characterize the natural history of chordoma, including clinical presentation and patterns of disease progression.

Eligibility:

  • Subjects with radiographically or histologically documented chordoma.
  • Age greater than or equal to 2 years old

Design:

  • This protocol is a subprotocol to protocol 19-C-0016: "Natural History and Biospecimen Acquisition Study for Children and Adults with Rare Solid Tumors". After enrollment on the master protocol and undergoing evaluations detailed, participants will be enrolled on this subprotocol specific for chordoma.
  • Medical histories will be documented, and participants followed throughout the course of their disease, with particular attention to patterns of disease recurrence and progression, response to therapies, duration of responses and patient reported outcomes. Tumor growth rates will also be calculated throughout the course of the disease.
03

Conditions studied

  • Chordoma

Browse trials for

Keywords

  • Rare Tumor
  • Comprehensive Evaluation and Recommendations
  • Collecting Clinical, Epidemiologic and Biological Data
  • Natural History
04

Who can participate

The criteria were revised on the registry on Oct 1, 2026. See what changed

Ages eligible
2 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

primary clinical

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ability of subject or Legally Authorized Representative (LAR) to understand and the willingness to sign a written consent document.
  • Subjects with radiographically or documented chordoma
  • Age >= 2 years old
  • Subjects must be enrolled into NCI protocol 19-C-0016: "Natural History and Biospecimen Acquisition Study for Children and Adults with Rare Solid Tumors".

Exclusion criteria

EXCLUSION CRITERIA:

-None

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
300 participants (estimated)

Groups and cohorts

  • 1/Cohort 1

    Subjects with confirmed chordoma.

06

What researchers measure

Primary outcomes

  1. To characterize the natural history of chordoma, including clinical presentation and patterns of disease progression

    Natural history of chordoma, including clinical presentation and patterns of disease progression

    Time frame: 10 years

07

Study locations

1 of 1 sites recruiting
  • National Institutes of Health Clinical Center
    Bethesda, Maryland 20892, United States
    Recruiting
    • For more information at the NIH Clinical Center contact National Cancer Institute Referral Office · Contact888-624-1937
08

References and documents

Publications

  • Wedekind MF, Widemann BC, Cote G. Chordoma: Current status, problems, and future directions. Curr Probl Cancer. 2021 Aug;45(4):100771. doi: 10.1016/j.currproblcancer.2021.100771. Epub 2021 Jul 1. PubMed 34266694 ↗

Individual participant data

Plan to share: Yes — All IPD recorded in the medical record will be shared with intramural investigators upon request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Clinical data available during the study and indefinitely.

Access criteria: Clinical data will be made available via subscription to BTRIS and with the permission of the study PI.

09

Timeline

6 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2019 (actual). Primary completion is estimated for Dec 2029, 128 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 9, 2019
First posted
Apr 10, 2019
StartActual
Apr 16, 2019
Primary completionEst.
Dec 31, 2029
CompletionEst.
Dec 31, 2029
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
2 inclusion criteria edited
What changed in the criteria
Inclusion criteria
  • EditedAge greater than or equal to>= 2 years old
  • EditedSubjects must be enrolled into NCI protocol 19-C-0016: "Natural History and Biospecimen Acquisition Study for Children and Adults with Rare Solid Tumors ".
Oct 1, 2026
Show all 6 updates
  1. Nov 9, 2026
    Minor edits only
    + 1 other change: description
  2. Nov 5, 2026
    Minor edits only
    + 1 other change: description
  3. Oct 26, 2026
    Minor edits only
    + 1 other change: description
  4. Oct 16, 2026
    Minor edits only
    + 2 other changes: verification date and description
  5. Oct 2, 2026
    Minor edits only
    + 1 other change: verification date
  6. Oct 1, 2026
    Eligibility 2 inclusion criteria edited
    What changed in the criteria
    Inclusion criteria
    • EditedAge greater than or equal to>= 2 years old
    • EditedSubjects must be enrolled into NCI protocol 19-C-0016: "Natural History and Biospecimen Acquisition Study for Children and Adults with Rare Solid Tumors ".
    + 1 other change: description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT03910465
Responsible party
Sponsor
First posted
Apr 10, 2019
Start date
Apr 16, 2019
Primary completion
Dec 31, 2029 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Nov 9, 2026

Study contacts

Barbara J Thomas, R.N.
Contact
barbara.thomas2@nih.gov
(240) 858-3633
Mary F Wedekind Malone, D.O.
Contact
maryfrances.wedekindmalone@nih.gov
(240) 858-3765
Mary F Wedekind Malone, D.O.
principal investigator · National Cancer Institute (NCI)

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion